We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

163 hedge funds and large institutions have $401M invested in Rigel Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 56 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $1.35M | Put options by funds: $750K

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

10% more capital invested

Capital invested by funds: $365M → $401M (+$35.7M)

1% more funds holding

Funds holding: 162 → 163 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.19% less ownership

Funds ownership: 8.07% → 7.88% (-0.19%)

11% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 56

Holders
163
Holders Change
+1
Holders Change %
+0.62%
% of All Funds
2.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
50
Reduced
56
Closed
16
Calls
$1.35M
Puts
$750K
Net Calls
+$597K
Net Calls Change
+$710K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$6.91M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.89M
3
IC
Ikarian Capital
Texas
+$4.6M
4
WP
Woodline Partners
California
+$2.23M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.54M
2
TA
Tamarack Advisers
California
-$3.38M
3
Goldman Sachs
Goldman Sachs
New York
-$3.13M
4
HP
HealthInvest Partners
Sweden
-$2.89M
5
State Street
State Street
Massachusetts
-$2.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
151
Cutler Group
California
$3K +$271 +10 +8%
CAPTRUST Financial Advisors
152
CAPTRUST Financial Advisors
North Carolina
$3K +$2.76K +102 +850%
Bessemer Group
153
Bessemer Group
New Jersey
$2K – – –
WAM
154
Worth Asset Management
Texas
$2K +$2.71K +100 New
Daiwa Securities Group
155
Daiwa Securities Group
Japan
$1K – – –
GI
156
Gradient Investments
Minnesota
$1K – – –
PA
157
Parallel Advisors
California
$1K +$541 +20 +182%
S
158
SignatureFD
Georgia
$1K +$948 +35 New
LC
159
Lindbrook Capital
California
$1K +$1K +37 New
HP
160
HealthInvest Partners
Sweden
– -$2.89M -109,000 Closed
SCM
161
Sio Capital Management
New York
– -$2.42M -91,362 Closed
AG
162
Artal Group
Luxembourg
– -$851K -32,110 Closed
SCP
163
Sender Company & Partners
New York
– -$518K -19,546 Closed
HT
164
HAP Trading
New York
– -$271K -9,996 Closed
PCM
165
Prelude Capital Management
New York
– -$183K -6,890 Closed
CM
166
Caption Management
Oklahoma
– -$99K -3,790 Closed
SG Americas Securities
167
SG Americas Securities
New York
– -$78K -2,931 Closed
SC
168
Shay Capital
New York
– -$75K -2,813 Closed
MC
169
Manteio Capital
New Jersey
– -$47K -1,759 Closed
RA
170
Royce & Associates
New York
– -$37K -1,412 Closed
ACM
171
Aquatic Capital Management
Illinois
– -$35K -1,320 Closed
JAM
172
Jupiter Asset Management
United Kingdom
– -$31K -1,162 Closed
VWA
173
Visionary Wealth Advisors
Illinois
– -$29K -1,092 Closed
EVM
174
Eaton Vance Management
Massachusetts
– -$2K -60 Closed
Carson Wealth (CWM LLC)
175
Carson Wealth (CWM LLC)
Nebraska
– +$190 +7 New
4 5 6
7
8

RIGL Hedge Fund Activity: Q1 2022 in Review

163 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2022, worth a combined $401M — up 9.8% from $365M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RIGL positions and 16 closed out — a net gain of 2 holders — while 50 added to existing stakes and 56 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $6.91M. The largest seller was Millennium Management, cutting an estimated $5.54M.

  • 163 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2022, up from 162 in Q4 2021.
  • Funds reported $401M of Rigel Pharmaceuticals stock for Q1 2022, up 9.8% quarter-over-quarter.
  • 18 funds opened new Rigel Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of +2 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2022 was Citadel Advisors, an estimated $6.91M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $5.54M sold.

Based on aggregated 13F filings for Q1 2022.